Reversing factor Xa inhibitors – clinical utility of andexanet alfa

Approximately half of patients started on an oral anticoagulant in the USA now receive one of the newer direct oral anticoagulants (DOACs). Although there is an approved reversal agent for the direct thrombin inhibitor dabigatran, a specific reversal agent for the anti-factor Xa (FXa) DOACs has yet...

Full description

Saved in:
Bibliographic Details
Published in:J Blood Med
Main Authors: Kaatz, Scott, Bhansali, Hardik, Gibbs, Joseph, Lavender, Robert, Mahan, Charles E, Paje, David G
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2017
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5602457/
https://ncbi.nlm.nih.gov/pubmed/28979172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S121550
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items